The Effect of Osteoporosis Medication on Risk Attenuation of Non-Trauma Fracture Among Adults with Cerebral Palsy: A Propensity Score-Matched Observational Study

References

• Christensen D, Van Naarden Braun K, Doernberg NS, et al. Prevalence of cerebral palsy, co-occurring autism spectrum disorders, and motor functioning – autism and developmental disabilities monitoring network, USA, 2008. Dev Med Child Neurol. 2014;56(1):59–65. doi:10.1111/dmcn.1226824117446
   PubMed Web of Science ®Google Scholar
• Maenner MJ, Blumberg SJ, Kogan MD, Christensen D, Yeargin-Allsopp M, Schieve LA. Prevalence of cerebral palsy and intellectual disability among children identified in two U.S. national surveys, 2011–2013. Ann Epidemiol. 2016;26(3):222–226. doi:10.1016/j.annepidem.2016.01.00126851824
   PubMed Web of Science ®Google Scholar
• Rosenbaum P, Paneth N, Leviton A, et al. A report: the definition and classification of cerebral palsy april 2006. Dev Med Child Neurol Suppl. 2007;109:8–14.17370477
   PubMedGoogle Scholar
• Rose J, McGill KC. Neuromuscular activation and motor-unit firing characteristics in cerebral palsy. Dev Med Child Neurol. 2005;47(5):329–336. doi:10.1017/S001216220500062915892375
   PubMed Web of Science ®Google Scholar
• Wiley ME, Damiano DL. Lower-extremity strength profiles in spastic cerebral palsy. Dev Med Child Neurol. 1998;40(2):100–107. doi:10.1111/j.1469-8749.1998.tb15369.x9489498
   PubMed Web of Science ®Google Scholar
• Elder GC, Kirk J, Stewart G, et al. Contributing factors to muscle weakness in children with cerebral palsy. Dev Med Child Neurol. 2003;45(8):542–550. doi:10.1111/j.1469-8749.2003.tb00954.x12882533
   PubMed Web of Science ®Google Scholar
• Whitney DG, Singh H, Miller F, et al. Cortical bone deficit and fat infiltration of bone marrow and skeletal muscle in ambulatory children with mild spastic cerebral palsy. Bone. 2017;94:90–97. doi:10.1016/j.bone.2016.10.00527732905
   PubMed Web of Science ®Google Scholar
• Johnson DL, Miller F, Subramanian P, Modlesky CM. Adipose tissue infiltration of skeletal muscle in children with cerebral palsy. J Pediatr. 2009;154(5):715–720. doi:10.1016/j.jpeds.2008.10.04619111321
   PubMed Web of Science ®Google Scholar
• Modlesky CM, Whitney DG, Singh H, Barbe MF, Kirby JT, Miller F. Underdevelopment of trabecular bone microarchitecture in the distal femur of nonambulatory children with cerebral palsy becomes more pronounced with distance from the growth plate. Osteoporos Int. 2015;26(2):505–512. doi:10.1007/s00198-014-2873-425199575
   PubMed Web of Science ®Google Scholar
• Al Wren T, Lee DC, Kay RM, Dorey FJ, Gilsanz V. Bone density and size in ambulatory children with cerebral palsy. Dev Med Child Neurol. 2011;53(2):137–141. doi:10.1111/j.1469-8749.2010.03852.x21166671
   PubMed Web of Science ®Google Scholar
• Whitney DG, Peterson MD, Devlin MJ, Caird MS, Hurvitz EA, Modlesky CM. Bone marrow fat physiology in relation to skeletal metabolism and cardiometabolic disease risk in children with cerebral palsy. Am J Phys Med Rehabil. 2018;97(12):911–919. doi:10.1097/PHM.000000000000098129894311
   PubMed Web of Science ®Google Scholar
• Stevenson RD, Conaway M, Barrington JW, Cuthill SL, Worley G, Henderson RC. Fracture rate in children with cerebral palsy. Pediatr Rehabil. 2006;9(4):396–403. doi:10.1080/1363849060066806117111566
   PubMedGoogle Scholar
• Whitney DG, Caird MS, Jepsen KJ, et al. Elevated fracture risk for adults with neurodevelopmental disabilities. Bone. 2020;130:115080. doi:10.1016/j.bone.2019.11508031655219
   PubMed Web of Science ®Google Scholar
• Whitney DG, Alford AI, Devlin MJ, Caird MS, Hurvitz EA, Peterson MD. Adults with cerebral palsy have higher prevalence of fracture compared with adults without cerebral palsy independent of osteoporosis and cardiometabolic diseases. J Bone Miner Res. 2019;34(7):1240–1247. doi:10.1002/jbmr.369430730595
   PubMed Web of Science ®Google Scholar
• Whitney DG, Hurvitz EA, Devlin MJ, et al. Age trajectories of musculoskeletal morbidities in adults with cerebral palsy. Bone. 2018;114:285–291. doi:10.1016/j.bone.2018.07.00229981509
   PubMed Web of Science ®Google Scholar
• Whitney DG, Bell S, Hurvitz EA, Peterson MD, Caird MS, Jepsen KJ. The mortality burden of non-trauma fracture for adults with cerebral palsy. Bone Rep. 2020;13:100725. doi:10.1016/j.bonr.2020.10072533088868
   PubMedGoogle Scholar
• Whitney DG, Whitney RT, Prisby RD, Jepsen KJ. Low-trauma fracture increases 12-month incidence of cardiovascular disease for adults with cerebral palsy. J Orthop Res. 2020;38(4):803–810.31710380
   PubMed Web of Science ®Google Scholar
• Whitney DG, Bell S, Etter JP, Prisby RD. The cardiovascular disease burden of non-traumatic fractures for adults with and without cerebral palsy. Bone. 2020;136:115376. doi:10.1016/j.bone.2020.11537632335375
   PubMed Web of Science ®Google Scholar
• Whitney DG. Nontrauma fracture increases risk for respiratory disease among adults with cerebral palsy. J Orthop Res. 2020.
   Web of Science ®Google Scholar
• Ryan JM, Peterson MD, Ryan N, et al. Mortality due to cardiovascular disease, respiratory disease, and cancer in adults with cerebral palsy. Dev Med Child Neurol. 2019;61(8):924–928. doi:10.1111/dmcn.1417630727025
   PubMed Web of Science ®Google Scholar
• Blair E, Langdon K, McIntyre S, Lawrence D, Watson L. Survival and mortality in cerebral palsy: observations to the sixth decade from a data linkage study of a total population register and national death index. BMC Neurol. 2019;19(1):111. doi:10.1186/s12883-019-1343-131164086
   PubMed Web of Science ®Google Scholar
• Shin YK, Yoon YK, Chung KB, Rhee Y, Cho SR. Patients with non-ambulatory cerebral palsy have higher sclerostin levels and lower bone mineral density than patients with ambulatory cerebral palsy. Bone. 2017;103:302–307. doi:10.1016/j.bone.2017.07.01528720522
   PubMed Web of Science ®Google Scholar
• Tian X, Jee WS, Li X, Paszty C, Ke HZ. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone. 2011;48(2):197–201. doi:10.1016/j.bone.2010.09.00920850580
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–1809. doi:10.1056/NEJMoa07494117878149
   PubMed Web of Science ®Google Scholar
• Crichton JU, Mackinnon M, White CP. The life-expectancy of persons with cerebral palsy. Dev Med Child Neurol. 1995;37(7):567–576. doi:10.1111/j.1469-8749.1995.tb12045.x7615144
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim SN, Lee IS, et al. Effects of bisphosphonates to treat osteoporosis in children with cerebral palsy: a meta-analysis. J Pediatr Endocrinol Metab. 2015;28(11–12):1343–1350. doi:10.1515/jpem-2014-052726214607
   PubMed Web of Science ®Google Scholar
• Sees JP, Sitoula P, Dabney K, et al. Pamidronate treatment to prevent reoccurring fractures in children with cerebral palsy. J Pediatr Orthop. 2016;36(2):193–197. doi:10.1097/BPO.000000000000042125757207
   PubMed Web of Science ®Google Scholar
• Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr. 2002;141(5):644–651. doi:10.1067/mpd.2002.12820712410192
   PubMed Web of Science ®Google Scholar
• Whitney DG, Kamdar NS, Ng S, Hurvitz EA, Peterson MD. Prevalence of high-burden medical conditions and health care resource utilization and costs among adults with cerebral palsy. Clin Epidemiol. 2019;11:469–481. doi:10.2147/CLEP.S20583931417318
   PubMed Web of Science ®Google Scholar
• Keshishian A, Boytsov N, Burge R, et al. Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. medicare population. J Manag Care Spec Pharm. 2017;23(11):1178–1190. doi:10.18553/jmcp.2017.1705429083977
   PubMed Web of Science ®Google Scholar
• Liu J, Guo H, Rai P, Pinto L, Barron R. Medication persistence and risk of fracture among female medicare beneficiaries diagnosed with osteoporosis. Osteoporos Int. 2018;29(11):2409–2417. doi:10.1007/s00198-018-4630-630022254
   PubMed Web of Science ®Google Scholar
• Whitney DG, Whibley D, Jepsen KJ. The effect of low-trauma fracture on one-year mortality rate among privately insured adults with and without neurodevelopmental disabilities. Bone. 2019;129:115060. doi:10.1016/j.bone.2019.11506031494304
   PubMed Web of Science ®Google Scholar
• Whitney DG, Whitney RT, Prisby RD, Jepsen KJ. Low-trauma fracture increases 12-month incidence of cardiovascular disease for adults with cerebral palsy. J Orthop Res. 2019;38(4):803–810. doi:10.1002/jor.2451531710380
   PubMed Web of Science ®Google Scholar
• Whitney DG, Bell S, McNamara NA, Hurvitz EA. The mortality burden attributable to nontrauma fracture for privately insured adults with epilepsy. Epilepsia. 2020;61(4):714–724. doi:10.1111/epi.1646532108937
   PubMed Web of Science ®Google Scholar
• Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8–27. doi:10.1097/00005650-199801000-000049431328
   PubMed Web of Science ®Google Scholar
• Whitney DG. Effectiveness of osteoporosis medication on site-specific fracture risk attenuation among adults with epilepsy. Epilepsia. 2020;61(11):2583–2592. doi:10.1111/epi.1670033090479
   PubMed Web of Science ®Google Scholar
• Zhao JG, Zeng XT, Wang J, Liu L. Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: a systematic review and meta-analysis. JAMA. 2017;318(24):2466–2482. doi:10.1001/jama.2017.1934429279934
   PubMed Web of Science ®Google Scholar
• Marciniak C, Gabet J, Lee J, Ma M, Brander K, Wysocki N. Osteoporosis in adults with cerebral palsy: feasibility of DXA screening and risk factors for low bone density. Osteoporos Int. 2016;27(4):1477–1484. doi:10.1007/s00198-015-3393-626576540
   PubMed Web of Science ®Google Scholar
• Berry JG, Berry SD. Caring for patients with neurological impairment: conversations between a pediatrician and geriatrician. JAMA Pediatr. 2018;172(9):795. doi:10.1001/jamapediatrics.2018.107929971353
   PubMed Web of Science ®Google Scholar
• Vohra R, Madhavan S, Sambamoorthi U, St Peter C. Access to services, quality of care, and family impact for children with autism, other developmental disabilities, and other mental health conditions. Autism. 2014;18(7):815–826. doi:10.1177/136236131351290224353274
   PubMed Web of Science ®Google Scholar
• Aisen ML, Kerkovich D, Mast J, et al. Cerebral palsy: clinical care and neurological rehabilitation. Lancet Neurol. 2011;10(9):844–852. doi:10.1016/S1474-4422(11)70176-421849165
   PubMed Web of Science ®Google Scholar
• Horner-Johnson W, Dobbertin K, Andresen EM, Iezzoni LI. Breast and cervical cancer screening disparities associated with disability severity. Womens Health Issues. 2014;24(1):e147–153. doi:10.1016/j.whi.2013.10.00924439941
   PubMed Web of Science ®Google Scholar
• McColl MA, Forster D, Shortt SE, et al. Physician experiences providing primary care to people with disabilities. Healthc Policy. 2008;4(1):e129–147.19377334
   PubMedGoogle Scholar
• Presedo A, Dabney KW, Miller F. Fractures in patients with cerebral palsy. J Pediatr Orthop. 2007;27(2):147–153. doi:10.1097/BPO.0b013e318031740317314638
   PubMed Web of Science ®Google Scholar
• Chen Q, Guo M, Ma X, Pu Y, Long Y, Xu Y. Adherence to teriparatide treatment and risk of fracture: a systematic review and meta-analysis. Horm Metab Res. 2019;51(12):785–791. doi:10.1055/a-1062-944731826274
   PubMed Web of Science ®Google Scholar
• Henderson RC, Kairalla JA, Barrington JW, Abbas A, Stevenson RD. Longitudinal changes in bone density in children and adolescents with moderate to severe cerebral palsy. J Pediatr. 2005;146(6):769–775. doi:10.1016/j.jpeds.2005.02.02415973316
   PubMed Web of Science ®Google Scholar
• French ZP, Caird MS, Whitney DG. Osteoporosis epidemiology among adults with cerebral palsy: findings from private and public administrative claims data. JBMR Plus. 2019;3(11):e10231. doi:10.1002/jbm4.1023131768490
   PubMedGoogle Scholar
• Cosman F, Crittenden DB, Ferrari S, et al. FRAME study: the foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res. 2018;33(7):1219–1226. doi:10.1002/jbmr.342729573473
   PubMed Web of Science ®Google Scholar
• Whitney DG. Prevalence of high-burden medical conditions among young and middle-aged adults with pediatric-onset medical conditions: findings from us private and public administrative claims data. Int J Health Policy Manag. 2019;8(11):629–635. doi:10.15171/ijhpm.2019.6231779288
   PubMed Web of Science ®Google Scholar
• Toro G, Moretti A, Paoletta M, De Cicco A, Braile A, Panni AS. Neglected femoral neck fractures in cerebral palsy: a narrative review. EFORT Open Rev. 2020;5(1):58–64. doi:10.1302/2058-5241.5.19001932071774
   PubMed Web of Science ®Google Scholar